All In Biotech

Drug Trial Radar · NCT06717698

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 465 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

465

Planned (sponsor's estimate)

Start

Dec 2, 2024

Primary completion

Sep 1, 2026

Study completion Sep 17, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Dec 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.

Conditions

  • Chronic Kidney Disease

Interventions

  • NNC0519-0130Drug

    NNC0519-0130 will be administered subcutaneously.

  • PlaceboDrug

    Placebo matching NNC0519-0130 will be administered subcutaneously.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in urinary albumin-to-creatinine ratio (UACR) at week 12Time frame: From baseline (week 0) to end of a given maintenance dose period (week 12)
  2. Change in urinary albumin-to-creatinine ratio (UACR) at week 24Time frame: From baseline (week 0) to end of a given maintenance dose period (week 24)
  3. Change in urinary albumin-to-creatinine ratio (UACR) at week 36Time frame: From baseline (week 0) to end of a given maintenance dose period (week 36)

Locations

147 sites in 14 countries. Site status is shown where the registry gives one.

  • N America Res Inst - San Dimas

    San Dimas, California · Active not recruiting

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California · Active not recruiting

  • Rocky Mount Reg VA Med-DN

    Aurora, Colorado · Completed

  • Northeast Research Institute

    Fleming Island, Florida · Active not recruiting

  • Encore Medical Research LLC

    Hollywood, Florida · Active not recruiting

  • Northeast Research Institute

    Saint Augustine, Florida · Active not recruiting

  • Clinical Research of Cent FL

    Winter Haven, Florida · Completed

  • Endeavor Health

    Skokie, Illinois · Completed

  • Velocity Clin. Res Valparaiso

    Valparaiso, Indiana · Active not recruiting

  • Elite Research Center

    Flint, Michigan · Completed

  • Clinical Research Consultants

    Kansas City, Missouri · Active not recruiting

  • Albany Medical College

    Albany, New York · Active not recruiting

  • Carteret Medical Group

    Morehead City, North Carolina · Active not recruiting

  • Brookview Hills Research Associates, LLC

    Winston-Salem, North Carolina · Active not recruiting

  • Davita Clinical Research

    El Paso, Texas · Active not recruiting

  • Clinical Advancement Center

    San Antonio, Texas · Active not recruiting

  • Tekton Research

    San Antonio, Texas · Completed

  • Providence Medical Research Center

    Spokane, Washington · Active not recruiting

  • Centro de Investigaciones Metabólicas

    City of Buenos Aires, Argentina · Active not recruiting

  • Instituto de Cardiología de Corrientes

    Corrientes, Argentina · Active not recruiting

  • Instituto de Investigaciones Clinicas Mar Del Plata

    Mar del Plata, Argentina · Active not recruiting

  • Centro Médico CIMEL

    Lanús Este, Buenos Aires, Argentina · Active not recruiting

  • Renalida

    Mar del Plata, Buenos Aires, Argentina · Active not recruiting

  • Castle Hill Medical Centre

    Castle Hill, New South Wales, Australia · Active not recruiting

  • Gosford Renal Research

    Gosford, New South Wales, Australia · Active not recruiting

  • Heart of Australia

    Chelmer, Queensland, Australia · Active not recruiting

  • Melbourne Renal Research Group

    Reservoir, Victoria, Australia · Not yet recruiting

  • Sunshine Hospital - Western Centre for Health Research and Education

    St Albans, Victoria, Australia · Active not recruiting

  • Hospital do Rim e Hipertensao Fundacao Oswaldo Ramos

    São Paulo, Brazil · Active not recruiting

  • Quanta Diagnóstico Nuclear / Medicina Nuclear Alto da XV

    Curitiba, Paraná, Brazil · Active not recruiting

  • Instituto Pró-Renal Brasil

    Curitiba, Paraná, Brazil · Active not recruiting

  • Centro de Diabetes Curitiba

    Curitiba, Paraná, Brazil · Active not recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting

  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.

    Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting

  • SRH - Zdrave EAD

    Bankya, Bulgaria · Active not recruiting

  • Medical centre Zdrave 1 OOD

    Kozloduy, Bulgaria · Active not recruiting

  • Nader Yabrudi - ASMPVBE Individual practice

    Smolyan, Bulgaria · Active not recruiting

  • Medical Centre Acad. Iv. Penchev EOOD

    Sofia, Bulgaria · Completed

  • Medical Centre Acad. Iv. Penchev EOOD

    Sofia, Bulgaria · Active not recruiting

  • USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology

    Sofia, Bulgaria · Active not recruiting

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.